What is AskBio?
AskBio operates as a fully integrated molecular medicine and technology enterprise with a global footprint. The company specializes in the advancement of gene therapeutics, maintaining a comprehensive pipeline that spans clinical-stage candidates for various high-need disease areas. Beyond its therapeutic research, AskBio possesses an extensive library of over 775 molecular and genetic medicine patents, alongside proprietary capsids and promoters that serve as the foundation for its technological edge. Headquartered in Research Triangle Park, North Carolina, with significant operations in Europe and the United States, the company functions as an independently operated subsidiary of Bayer. Its infrastructure includes modern clinical and commercial manufacturing facilities, enabling a seamless transition from laboratory research to large-scale production.
How much funding has AskBio raised?
AskBio has raised a total of $4.2M across 2 funding rounds:
Grant
$1.6M
Grant
$2.6M
Grant (2004): $1.6M with participation from Muscular Dystrophy Association
Grant (2020): $2.6M led by Scottish Enterprise
Key Investors in AskBio
Scottish Enterprise
A national economic development agency and non-departmental public body of the Scottish Government, focused on fostering innovation and economic growth.
Muscular Dystrophy Association
A prominent non-profit organization dedicated to funding research and providing community services for individuals affected by muscular dystrophy and related neuromuscular diseases.
What's next for AskBio?
Looking ahead, the strategic focus for AskBio involves the continued expansion of its clinical-stage pipeline and the optimization of its cGMP manufacturing capabilities. As a subsidiary of Bayer, the company is well-positioned to leverage global distribution networks and regulatory expertise to accelerate the commercialization of its gene therapy candidates. The recent capital allocation will likely be directed toward enhancing its synthetic biology platforms and deepening its research into central nervous system disorders. By maintaining its focus on high-impact therapeutic innovation, AskBio is poised to remain at the forefront of the biotechnology sector, driving long-term value through its unique combination of proprietary technology and clinical excellence.
See full AskBio company page
